Identity and synonyms
Glu-Asp-Arg is stated in PMID21978084; no terminal or counterion claim is made about supplier material.
Peptide or peptide-related · Peptide or peptide derivative
Detailed molecular class: Tripeptide
Supplied sequence or chemical reference
See identity note; no supplier sequence accepted as verification.
Mechanism
Oxidative-stress and cell-survival pathways studied.
Evidence and critical reading
Reported scientific and empirical uses
Aging research · Cognition and neurology
Tripeptide promoted for neuroprotection, oxidative stress and longevity.
Human evidence
A small geriatric report exists, but its abstract has inconsistent sample accounting and does not establish anti-aging efficacy.
Preclinical evidence
Cell experiments report ROS and viability changes.
Critical reading and limitations
Cell experiments and a small geriatric report do not prove rejuvenation or general genetic safety.
Evidence applies to the exact molecule, formulation, route, population and endpoint studied. Supplier identity, purity and clinical equivalence are unverified.
Source-specific regimens
Descriptive source observations, not individual recommendations.
Regulatory product labeling
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Human-study exposure
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Empirical handbook
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Regulation and safety
Jurisdiction-specific regulatory context
Jurisdiction-specific approval not verified in this card; do not infer global nonapproval.
Adverse effects and unknowns
Human safety, contraindications and interactions are not adequately established for the catalog product. Missing reports are not evidence of safety.
The geriatric abstract has inconsistent participant accounting; it cannot estimate rare events.
Contraindications
See supported safety statements and exact product label; a complete contraindication set has not been established for this catalog material.
A complete list must match the exact authorized product. For experimental materials without verified human labeling, a complete contraindication set is not established here. No list does not mean safety.
Interactions
Only explicitly cited interactions may be asserted; unstudied combinations remain unknown, not interaction-free.
Separate documented interaction, pharmacologic plausibility and unknown interaction. Absence of a blend trial does not establish compatibility.
Studies and trials
Selected studies
PMID22117547 · Cell experiment
HeLa cells/DNA assays.
Fluorescent peptides, in vitro.
Nuclear penetration/DNA interaction.
Labeling/culture are not patient-vial distribution or benefit.
Trials attributed in the package
No trials are attributed in this record.
Trial registration does not establish efficacy or validate commercial material.
Query candidates; attribution pending
Pinealon · 0 unfiltered query results, not authenticated trials
Query verification: October 16, 2026
Exact phrase intervention query; first three most recently updated records, not exhaustive. Aliases may be missed and heterogeneous products may appear. The total is the unfiltered registry query count, not authenticated trials. Source-integrity holds are excluded from ordinary listings.
View trial registry querySource issues and references
References include queries and bibliographic handbook attributions; not all are clinical studies. Human review remains pending.
- PMID21978084
Khavinson V, Ribakova Y, Kulebiakin K, Vladychenskaya E, Kozina L, Arutjunyan A, Boldyrev A.
October 16, 2026
- PMID22117547
Fedoreyeva LI, Kireev II, Khavinson VKh, Vanyushin BF.
October 16, 2026
- PMID26390612
Meshchaninov VN, Tkachenko EL, Zharkov SV, Gavrilov IV, Katyreva IuE.
October 16, 2026
- pdf01
PEPNEXA 2.pdf
October 16, 2026
- pdf05
PEPNEXA.pdf
October 16, 2026
- pdf07
US Peptide MangerCorp(1).pdf
October 16, 2026
- pdf09
PeptideFactory.pdf
October 16, 2026